Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236356 | 1.00 | GAA (0.43) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4867930 | 0.88 | ALDH1A1 (0.40) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6236539 | 0.88 | ALDH1A1 (0.40) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6231440 | 0.87 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBN | |
| SCHEMBL4869754 | 0.86 | CYP3A4 (0.42) | ALDH1A1SMN1; SMN2TSHRHTR2CCPB1 | |
| SCHEMBL6235063 | 0.85 | CTSL (0.46) | ALDH1A1FKBP1ADDB1CRBN | |
| SCHEMBL6234929 | 0.85 | CTSL (0.46) | ALDH1A1FKBP1ADDB1CRBN | |
| SCHEMBL4867759 | 0.84 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL25317301 | 0.78 | ALDH1A1 (0.51) | ALDH1A1DDB1CRBN | |
| SCHEMBL4868091 | 0.77 | CYP3A4 (0.41) | ALDH1A1SMN1; SMN2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | GAA 1043/4885ALDH1A1 4302/4885NPC1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.